checkpoint blockade

There have been remarkable results of anti-PD1 causing remissions in heavily pretreated Hodgkin's Lymphoma patients.

Here we examine why this cancer immunotherapy can change the way Hodgkin's Lymphoma patients are treated in the future.

Hodgkin's Lymphoma is a good target for anti-PD1.

This is an excellent video explaining immunotherapy in lung cancer, primarily focusing on anti-PD1.

This video was published November 4, 2014 by Global Resource for Advancing Cancer Education (GRACE).

Dr. Jack West (Swedish Cancer Center, Seattle) moderates this discussion with Dr. Julie Brahmer (John Hopkins, Baltimore) and Dr. Ben Creelan (Moffitt Cancer Center, Tampa).

A patient was on Yervoy for many months but progressed. A painful spinal lung met developed. The clinicians (Dr. James Allison's colleagues at Memorial Sloan in New York) decided to irradiate for pain relief. Amazingly, one month later, when Yervoy was resumed, all other progressing tumors regressed (not just the sole irradiated tumor). They documented this exciting finding in a case report.

Back in 2009, when I began my quest to understand Coley's Toxins, my wife's boss at the university connected us with a very special human being. His name was Dr. Lloyd Old, once former Vice President at Memorial Sloan Kettering Cancer Center, but in recent years before his passing away, fully dedicated chief of the Ludwig institute for Cancer Research (or LICR). LICR is a well funded non-profit research organization that sponsors and nurtures a large worldwide collaborative of leading researchers in the field of cancer immunotherapy.

A few days ago, I was scanning google scholar for the latest research on checkpoint blockade immunotherapy. I found a good paper that explains the current state cancer advances in the field of immunotherapy, including recent advances in checkpoint blockade:

Here's a link to that journal paper entitled "Cancer Immunotherapy comes of Age"

Embedded within the paper was the following important point: